All In Biotech

Drug Trial Radar · NCT04324164

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Mar 24, 2020

Primary completion

Dec 24, 2025

Study completion Dec 24, 2027

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 27, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Third-generation EGFR-TKIDrug

    Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

  • EGFR-TKIDrug

    All EGFR-TKI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yongchang Zhang

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.